我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
• The FDA has approved omidubicel for patients with blood cancers requiring allogeneic hematopoietic stem cell transplant (HSCT). • A phase 3 trial showed omidubicel significantly reduced the median time to neutrophil engraftment compared to standard umbilical cord blood (UCB) grafts. • Omidubicel offers a new option for stem cell source, potentially improving outcomes for patients ineligible for traditional transplants. • The approval underscores the FDA's commitment to innovative therapies for life-threatening cancers, providing a new treatment option.
